Trapelo Health announced a first-of-its-kind collaboration with Texas Oncology and Superior HealthPlan aimed at bringing the latest advancements in precision oncology to more cancer patients throughout Texas. Read the full release.
Collaboration gives Magellan Rx customers a first-of-its-kind solution to address the complexities of precision medicine. Read the full release.
Listen to an in-depth interview with Dr. Caroline Carney and Clynt Taylor on the Precision Medicine Podcast.
Trapelo will continue to serve oncologists, labs and payers in fulfilling its mission to resolve the complexities of precision oncology in real-time, but with the added backing and resources of NeoGenomics. Read the full release.
Subscribe for an upcoming interview on the Precision Medicine Podcast.
Partnership Seeks to Lower Barriers to Evidence-Based Molecular Oncology Care by Extending Trapelo’s Decision Support Solutions Through Concert’s Network of Laboratories and Health Plans Read the full release.
Listen to an in-depth interview on the Precision Medicine Podcast.
Clynt Taylor, CEO of Intervention Insights, announced this week that the company has officially changed its name to Trapelo Health. Taylor explained that the new name reflects a commitment to the company’s platform, Trapelo, which launched in December 2018. Full release.
Intervention Insights welcomes respected healthcare leader Chet Burrell as its Executive Chairman to support the continued growth of its distinct, precision diagnostic platform Trapelo. Full multi-media release.
Intervention Insights announces the appointment of Dr. Lee Newcomer, former UnitedHealthcare executive and Medical Director for Cigna Healthcare, to its Board of Directors to support the growth of its distinct, precision medicine platform Trapelo.
Intervention Insights is collaborating with City of Hope, a world-renowned independent cancer research and treatment center, to advance the appropriate use of precision medicine in oncology. By working with Intervention Insights and leveraging Trapelo™, its evidence-based technology platform, the organization will demonstrate new ways to incorporate precision medicine decision support at the point of care. Full multi-media release.
Trapelo™ enables oncologists to identify in real time the right patients for molecular testing and the right tests to perform by preferred labs for actionable results that lead to faster, more targeted treatment choices when time matters most.
WALTHAM, MA – December 7, 2017: Intervention Insights is pleased to announce the availability of Trapelo, a true advancement in the use of molecular science and targeted therapies for cancer patients. The first-of-its-kind, decision support, order management and results reporting solution for molecular testing enables real-time alignment among oncologists, labs and payers in the dynamic and increasingly complex world of precision medicine. Read more.